These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17460704)

  • 41. Rare-event analysis in flow cytometry.
    Donnenberg AD; Donnenberg VS
    Clin Lab Med; 2007 Sep; 27(3):627-52, viii. PubMed ID: 17658410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural killer function in flow cytometry: identification of human lymphoid subsets able to bind to the NK sensitive target K562.
    Vitale M; Zamai L; Neri LM; Manzoli L; Facchini A; Papa S
    Cytometry; 1991; 12(8):717-22. PubMed ID: 1838975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Flow cytometric analysis of lymphomas and lymphoproliferative disorders.
    Stetler-Stevenson M; Braylan RC
    Semin Hematol; 2001 Apr; 38(2):111-23. PubMed ID: 11309693
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Flow cytometric immunophenotyping in posttransplant lymphoproliferative disorders.
    Dunphy CH; Gardner LJ; Grosso LE; Evans HL
    Am J Clin Pathol; 2002 Jan; 117(1):24-8. PubMed ID: 11789726
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Setting up and calibration of a flow cytometer for multicolor immunophenotyping.
    Kraan J; Gratama JW; Keeney M; D'Hautcourt JL
    J Biol Regul Homeost Agents; 2003; 17(3):223-33. PubMed ID: 14524607
    [No Abstract]   [Full Text] [Related]  

  • 46. Flow cytometric immunophenotyping of plasmacytic neoplasms.
    DiGiuseppe JA
    Am J Clin Pathol; 2007 Feb; 127(2):172-4. PubMed ID: 17210527
    [No Abstract]   [Full Text] [Related]  

  • 47. A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B-cell chronic lymphoproliferative disorders.
    Pedreira CE; Costa ES; Almeida J; Fernandez C; Quijano S; Flores J; Barrena S; Lecrevisse Q; Van Dongen JJ; Orfao A;
    Cytometry A; 2008 Dec; 73A(12):1141-50. PubMed ID: 18836994
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimization of a flow cytometry-based protocol for detection and phenotypic characterization of multipotent mesenchymal stromal cells from human bone marrow.
    Jones EA; English A; Kinsey SE; Straszynski L; Emery P; Ponchel F; McGonagle D
    Cytometry B Clin Cytom; 2006 Nov; 70(6):391-9. PubMed ID: 16977637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A practical approach to the flow cytometric detection and diagnosis of T-cell lymphoproliferative disorders.
    Meyerson HJ
    Lab Hematol; 2010 Sep; 16(3):32-52. PubMed ID: 20858587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flow cytometry: an overview.
    Villas BH
    Cell Vis; 1998; 5(1):56-61. PubMed ID: 9660728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced multi-FISH analysis of immunophenotyped plasma cells by imaging flow cytometry.
    Erber WN; Hui HYL; Mincherton TI; Harms M; Clarke S; Fuller KA
    J Hum Genet; 2023 Jul; 68(7):515-516. PubMed ID: 37161034
    [No Abstract]   [Full Text] [Related]  

  • 52. Flower-Like Plasma Cell: A Comment.
    Gajendra S
    Turk J Haematol; 2021 Aug; 38(3):228-229. PubMed ID: 33906332
    [No Abstract]   [Full Text] [Related]  

  • 53. Issue highlights--November 2014.
    McCoy JP
    Cytometry B Clin Cytom; 2014 Nov; 86(6):371-2. PubMed ID: 25336149
    [No Abstract]   [Full Text] [Related]  

  • 54. Evolving progress in the management of malignant plasma cell disorders.
    Atilgan E; Gonsalves WI
    Cancer Treat Res Commun; 2022; 32():100612. PubMed ID: 35872008
    [No Abstract]   [Full Text] [Related]  

  • 55. Utility of flow cytometry screening before MRD testing in multiple myeloma.
    Panakkal V; Lakshman A; Shi M; Olteanu H; Horna P; Timm MM; Otteson GE; Baughn LB; Greipp PT; Gonsalves WI; Kapoor P; Gertz MA; Binder M; Buadi FK; Dispenzieri A; Rajkumar SV; Kumar SK; Jevremovic D
    Blood Cancer J; 2023 Apr; 13(1):55. PubMed ID: 37080968
    [No Abstract]   [Full Text] [Related]  

  • 56. High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics.
    Xia Y; Shen N; Zhang R; Wu Y; Shi Q; Li J; Chen L; Xu M; Jin Y
    Front Oncol; 2023; 13():1083053. PubMed ID: 36845679
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenström macroglobulinemia.
    Lim JH; Wang JQ; Webb F; Saxena K; Enosi Tuipulotu D; Pandey A; Man SM; Talaulikar D
    iScience; 2022 Aug; 25(8):104856. PubMed ID: 35992066
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Expression of CD45 in newly diagnosed multiple myeloma and the relationship with prognosis].
    Shi J; Zhu ZM; Sun K; Lei PC; Liu ZW; Guo JM; Yang J; Zang YZ; Zhang Y
    Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):744-749. PubMed ID: 31648475
    [No Abstract]   [Full Text] [Related]  

  • 59. Impact of acquired del(17p) in multiple myeloma.
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Adv; 2019 Jul; 3(13):1930-1938. PubMed ID: 31248884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multiple Myeloma Exemplifies a Model of Cancer Based on Tissue Disruption as the Initiator Event.
    Capp JP; Bataille R
    Front Oncol; 2018; 8():355. PubMed ID: 30250824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.